Cellectar Biosciences enters partnership with CPDC
Cellectar Biosciences announced it has selected Hamilton, Ontario-based Centre for Probe Development and Commercialization, or CPDC, a well-respected GMP manufacturing organization specializing in radiopharmaceuticals, as a supplier of the company's lead phospholipid drug conjugate, or PDC, CLR 131. The company believes that CPDC will provide a cost-effective and long-term manufacturing solution. The partnership establishes manufacturing capacity at a level sufficient for both a pivotal trial and future large-scale commercial production. CPDC's development of further production capability for CLR 131 will significantly enhance the company's ability to support the anticipated clinical trial activity as it progresses through 2017 while also preparing for a pivotal study and, ultimately, commercialization.